PML nuclear bodies: regulation, function and therapeutic perspectives

J Pathol. 2014 Nov;234(3):289-91. doi: 10.1002/path.4426.


PML nuclear bodies (NBs) were first described by electron microscopy and rediscovered through their treatment-reversible disruption in a rare leukaemia. They recruit multiple partner proteins and now emerge as interferon- and oxidative stress-responsive sumoylation factories. NBs mediate interferon-induced viral restriction, enhance proteolysis, finely tune metabolism and enforce stress-induced senescence. Apart from being markers of cellular stress, PML NBs could be harnessed pharmacologically in a number of conditions, including cancer, viral infection or neurodegenerative diseases.

Keywords: PML; RNF4; arsenic; interferon; oxidative stress; p53; senescence.

Publication types

  • Review

MeSH terms

  • Animals
  • Humans
  • Intranuclear Inclusion Bodies*
  • Nuclear Proteins*
  • Promyelocytic Leukemia Protein
  • Transcription Factors*
  • Tumor Suppressor Proteins*


  • Nuclear Proteins
  • Promyelocytic Leukemia Protein
  • Transcription Factors
  • Tumor Suppressor Proteins
  • PML protein, human